

Special Issue

Novel Antibacterial, Antibiofilm and Anti-virulence Candidates

Message from the Guest Editors

The growing microbial resistance to antibiotics is an increasingly challenging issue that global health faces. The dwindling discovery of new antibiotics worsens the situation and mandates new approaches and strategies to conquer microbial resistance. Bacteria recruit diverse virulence factors and employ several systems to control the regulation of these virulence arsenals. Among the most resistant microbial phenotypes, bacterial biofilms constitute a huge obstacle against efficient antibiotic treatments. Targeting bacterial virulence and diminishing biofilms greatly attenuates bacteria and eases their eradication through antibiotics. Targeting virulence can be achieved by targeting virulence-controlling systems. Among the most involved virulence-controlling systems, quorum sensing (QS) plays a crucial role in orchestrating the production of bacterial virulence factors and biofilms. Moreover, several approaches have been suggested to eradicate bacterial biofilms and inhibit bacterial virulence. This issue focuses on the discovery of new antibacterial and antibiofilm candidates to serve as adjuvants to antibiotics in the treatment of aggressive infections.

Guest Editors

Dr. Wael Hegazy

Dr. Amr S. Abu Lila

Dr. Tarek S. Ibrahim

Deadline for manuscript submissions

closed (30 November 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/151066

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).